Angiotensin Receptor Blockers (ARBs) Market Forecast Reveals Where Future Industry Value Will Be Created
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Angiotensin Receptor Blockers (ARBs) Market CAGR Analysis And Future Market Development
The angiotensin receptor blockers (ARBs) market has experienced consistent expansion over the past few years. Valued at $8.78 billion in 2025, it is projected to reach $9.18 billion by 2026, reflecting a compound annual growth rate (CAGR) of 4.6%. This historical growth has been driven by factors such as the increasing incidence of hypertension, heightened awareness surrounding cardiovascular conditions, the broadening reach of hospital networks, the launch of novel ARB compounds, and intensified research efforts into therapies for kidney disease.
The angiotensin receptor blockers (ARBs) market is projected to experience consistent expansion over the coming years. By 2030, its value is anticipated to reach $11.02 billion, driven by a compound annual growth rate (CAGR) of 4.7%. This anticipated growth in the forecast period is fueled by several factors, including an increasingly older population, a rising preference for personalized medical approaches, innovations in drug delivery technologies, heightened healthcare spending, and the broadening network of specialty clinics. Key developments shaping this period include a shift toward tailored hypertension management, a greater focus on therapies for chronic kidney disease, the widening application of cardiovascular treatments, the growing adoption of oral ARB formulations, and an increase in prescriptions issued by hospitals and specialty clinics.
Download A Free Sample Report For Comprehensive Market Insights:
Angiotensin Receptor Blockers (ARBs) Market Demand Drivers: What Is Fueling Industry Growth?
The growing prevalence of cardiovascular conditions is anticipated to drive expansion in the angiotensin receptor blockers market in the coming period. Cardiovascular disease (CVD) refers to any disorder impacting the heart or blood vessels, often linked to the accumulation of fatty deposits in arteries (atherosclerosis) and a heightened likelihood of clot formation. By facilitating relaxation in veins and arteries, angiotensin receptor blockers lower blood pressure and enhance the heart’s ability to pump blood, thereby reducing the risk of cardiovascular disease. As an example, in January 2024, the American Heart Association, a nonprofit organization based in the United States, reported that the age-adjusted death rate from cardiovascular disease climbed to 233.3 per 100,000 in 2024, marking a 4.0% rise from 224.4 per 100,000 in 2023. Consequently, the rising incidence of cardiovascular diseases is fueling growth in the angiotensin receptor blockers market.
The escalating occurrence of hypertension conditions is expected to drive forward the expansion of the angiotensin receptor blockers (ARBs) market. Hypertension, commonly referred to as high or elevated blood pressure, is a condition marked by persistently high pressure within blood vessels. Angiotensin receptor blockers (ARBs) represent a class of medications frequently prescribed for managing hypertension, working primarily by relaxing and widening blood vessels to allow more space for blood flow. As a result, a growing number of hypertension cases among individuals will boost the need for angiotensin receptor blockers. For instance, in March 2023, the World Health Organization, an intergovernmental entity based in Switzerland, noted that around 1.28 billion adults aged 30 to 79 worldwide have hypertension, with most (two-thirds) living in low- and middle-income nations. It is estimated that 46% of adults with hypertension are unaware they have the condition. Hence, the rising prevalence of hypertension diseases is propelling growth in the angiotensin receptor blockers (ARBs) market.
Angiotensin Receptor Blockers (ARBs) Market Segment Performance And Strategic Opportunities
The angiotensin receptor blockers (arbs) market covered in this report is segmented –
1) By Product: Valsartan, Telmisartan, Losartan, Irbesartan, Azilsartan, Olmesartan
2) By Application: Hypertension, Cardiovascular Diseases, Kidney Diseases, Other Applications
3) By End User: Hospitals, Specialty Clinics, Ambulatory Surgical Centers
Angiotensin Receptor Blockers (ARBs) Market Innovation Trends: Which Developments Are Transforming The Industry?
Prominent players in the angiotensin receptor blocker market are focusing on the development of innovative products, like angiotensin receptor neprilysin inhibitors, to broaden therapeutic options and improve patient outcomes in cardiovascular diseases. Angiotensin receptor neprilysin inhibitors, commonly referred to as ARNIs, represent a drug category designed for managing heart failure. A notable example occurred in January 2023, when Glenmark Pharmaceuticals, a pharmaceutical company headquartered in India, introduced sacubitril + valsartan tablets. These tablets are specifically formulated for heart failure treatment, particularly targeting heart failure with reduced ejection fraction, or HFrEF. This combination medication belongs to the ARNI class, as it incorporates both an angiotensin receptor blocker and a neprilysin inhibitor. Sacubitril works by boosting the natriuretic peptide system, helping to reduce fluid retention and facilitate vasodilation, whereas valsartan inhibits the renin-angiotensin system, thereby lowering blood pressure and decreasing cardiac strain. When used together, these components effectively enhance heart failure symptoms, lower the likelihood of cardiovascular death, and reduce the frequency of hospital admissions related to heart failure. Marketed under the trade name Sacu V, this product exemplifies the advancements in this therapeutic area.
Angiotensin Receptor Blockers (ARBs) Market Key Players: Which Companies Shape Industry Competition?
Major companies operating in the angiotensin receptor blockers (arbs) market are Pfizer Inc., Novartis AG, Merck & Co. Inc., AstraZeneca Plc., Bristol-Myers Squibb Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Lupin Limited, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Johnson & Johnson, Eli Lilly, Bayer AG, AbbVie Inc., Mylan N.V., Sun Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Zydus Cadila, Glenmark Pharmaceuticals Ltd., Cipla Ltd., Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Zhejiang Huahai Pharmaceutical Co. Ltd., Boehringer Ingelheim Ltd., Astellas Pharma, Thermo Fisher Scientific.
Access The Complete Angiotensin Receptor Blockers (ARBs) Market Report:
Angiotensin Receptor Blockers (ARBs) Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the angiotensin receptor blockers (ARBs) market share in 2025. The regions covered in the angiotensin receptor blockers (arbs) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
